HSK21542 Injection

DRUG3 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Chronic Kidney Disease PatientsPostoperative AnalgesiaRenal Impairment

Phase 1

A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment

Haisco Pharmaceutical Group Co., Ltd.Renal Impairment

Start: 2023-04-24End: 2023-12-30Target: 32Updated: 2023-07-17

Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

CompletedNCT06238388

Haisco Pharmaceutical Group Co., Ltd.Chronic Kidney Disease Patients

Start: 2023-10-10End: 2024-02-27Updated: 2024-08-20

Phase 3

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment

CompletedNCT05390905

Haisco Pharmaceutical Group Co., Ltd.Postoperative Analgesia

Start: 2022-06-08End: 2023-03-28Updated: 2023-04-04

Related Papers

HSK21542 in patients with postoperative pain: two phase 3, multicentre, double-blind, randomized, controlled trials

Nature Communications2025-05-245 citations